BHVN

Biohaven Ltd.
CAPPED RATING

Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological and neuropsychiatric diseases, and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as developing Rimegepant for preventive treatment of migraine; Zavegepant that is in phase III clinical trials for acute and preventive treatment of migraine, as well as respiratory complications and non-migraine studies; and BHV-3100 for non-migraine indications. The company also offers Troriluzole for spinocerebellar ataxia and obsessive compulsive disorders, as well as Alzheimer diseases; BHV-0223, a product for amyotrophic lateral sclerosis; BHV-5000/5500 for neuropsychiatric indications; and Verdiperstat, a product for multiple system atrophy and amyotrophic lateral sclerosis. Biohaven Pharmaceutical Holding Company Ltd. has a collaboration agreement with Cove to facilitate telemedicine evaluation for migraine sufferers. The company was incorporated in 2013 and is headquartered in New Haven, Connecticut.

Biohaven Ltd. (BHVN) is rated D (1.5/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Momentum (B); its weakest is Revisions (F). The rating has held at D for 6 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
1.5 / 5.0
D
Value
C+
Factor Score 2.5 / 5.0
Growth
D
Factor Score 1.2 / 5.0
Profitability
F
Factor Score 0.4 / 5.0
Momentum
B
Factor Score 3.3 / 5.0
Revisions
F
Factor Score 0.0 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -9.0
EV / EBITDA -4.7
Rev Growth YoY N/A
Gross Margin 0.0%
Price Return 3M 1.7%
Price Return 12M 70.8%
Catalyst Signal 0.00
Market Cap $2.1B
TTM Revenue N/A
Price / Sales N/A
ROE N/A

Historical Factor Score Progression

Held D for 6 weeks
Date Value Growth Profitability Momentum Revisions Overall
2026-11-17 C+ (2.5) D (1.2) F (0.4) B (3.3) F (0.0) D (1.5)
2026-11-10 C+ (2.5) F (0.7) F (0.4) B (3.5) F (0.0) D (1.4)
2026-11-03 C+ (2.5) F (0.5) F (0.4) B (3.3) F (0.0) D (1.4)
2026-10-27 C+ (2.5) F (0.7) F (0.3) B- (3.1) F (0.0) D (1.3)
2026-10-20 C+ (2.5) D- (0.9) F (0.3) C (2.4) F (0.0) D (1.2)
Page 1 of 4